Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2012 (2012), Article ID 637316, 7 pages
Review Article

New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration

Department of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, No. 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Republic of Korea

Received 30 July 2011; Accepted 3 November 2011

Academic Editor: Yoshiaki Kiuchi

Copyright © 2012 Young Gun Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients respond to monotherapy, and modified anti-VEGF treatment regimen and combination therapy may target reducing treatment frequency or improving visual outcome. This paper reviews the many clinical trials that have been performed utilizing several treatment regimens. While many trials have shown that this variable therapy is justifiable, further study is required to determine correct regimens and dosage.